Hepatic impairment No dose adjustment is necessary in people with mild or moderate (Baby-Pugh A or B) hepatic impairment (see segment 5.2). Exposure to midostaurin and its active metabolite CGP62221 is significantly reduced in clients with severe hepatic impairment than that in individuals with regu